当前位置: X-MOL 学术Lancet Psychiatry › 论文详情
Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis.
The Lancet Psychiatry ( IF 16.209 ) Pub Date : 2020-08-20 , DOI: 10.1016/s2215-0366(20)30264-9
Jose M Rubio,Georgios Schoretsanitis,Majnu John,Jari Tiihonen,Heidi Taipale,Daniel Guinart,Anil K Malhotra,Christoph U Correll,John M Kane

Background

Most individuals with schizophrenia-spectrum disorders have relapses, which increase the risk of morbidity and mortality. Because non-adherence to antipsychotic maintenance treatment could affect more than half of individuals with schizophrenia-spectrum disorders, psychosis relapse can often be confounded by unnoticed treatment interruption. Research of relapse during confirmed antipsychotic exposure has basic clinical and neurobiological implications, but data are scarce. We aimed to generate reliable estimates of incidence and predictors of relapse during assured antipsychotic treatment.

Methods

We did a systematic review and individual participant data (IPD) meta-analysis of clinical trials of long-acting injectable antipsychotics (LAIs) for psychosis relapse-prevention, following IPD-PRISMA guidelines. Datasets were identified by searching relevant repositories from inception to Aug 1, 2019. Each LAI group was reanalysed as a separate cohort, further identifying subcohorts of individuals with and without prospectively determined symptom remission (PSR). Summary incidence rate of relapse, incidence rate ratios (IRRs) of relapse between individuals with and without PSR, hazard ratios (HRs) of covariates on risk of relapse, and standardised mean difference (SMDs) in changes in overall functioning associated with relapse were generated by pooling results from the harmonised reanalysis of each study. This study is registered with PROSPERO, number CRD42019137439.

Findings

19 treatment cohorts consisting of 5130 individuals (2938 with PSR, 2192 without PSR), with 3959·53 observed participant-years, were meta-analysed. Pooled incidence of relapse was 22·97 per 100 participant-years (14·76 per 100 participant-years for the PSR subcohort, 31·51 per 100 participant-years for the non-PSR subcohort), with an IRR of 0·19 (95% CI 0·07 to 0·54). Relapse was associated with functional decline (overall SMD −0·76, 95% CI −1·14 to −0·37; PSR SMD −0·52, 95% CI −0·80 to −0·21; non-PSR SMD −0·72, 95% CI −1·18 to −0·26). The strongest predictor of relapse was tardive dyskinesia at treatment onset (HR 2·39, 95% CI 1·05 to 5·42).

Interpretation

Despite the established efficacy of antipsychotics in preventing relapse, these data indicate that these drugs might not prevent subsequent exacerbations for a proportion of individuals whose illness is stabilised on continuous antipsychotic treatment. Tardive dyskinesia in particular might have pathophysiological implications for relapse.

Funding

Northwell Health.

更新日期:2020-08-20
全部期刊列表>>
施普林格,自然编辑
ERIS期刊投稿
欢迎阅读创刊号
自然职场,为您触达千万科研人才
spring&清华大学出版社
城市可持续发展前沿研究专辑
Springer 纳米技术权威期刊征稿
全球视野覆盖
施普林格·自然新
chemistry
物理学研究前沿热点精选期刊推荐
自然职位线上招聘会
欢迎报名注册2020量子在线大会
化学领域亟待解决的问题
材料学研究精选新
GIANT
ACS ES&T Engineering
ACS ES&T Water
屿渡论文,编辑服务
ACS Publications填问卷
阿拉丁试剂right
林亮
南方科技大学
朱守非
华东师范大学
胡少伟
有机所林亮
隐藏1h前已浏览文章
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
上海纽约大学
浙江大学
廖矿标
天合科研
x-mol收录
试剂库存
down
wechat
bug